Page 13 - Flipbook

ERSPC (European Randomized Study of Screening

for Prostate Cancer)

• 162 243 men aged 55 to 69 years

• PSA screening once q1-4 years or an unscreened control group

• Median f/u 11 years

• The cumulative incidence of PCa was 8.2% in the screened group

vs 4.8%

• PCa death was reduced by 21% and 29% after adjustment for

noncompliance

• 9 years (NNS 1410, NND 48)

• 11 years (NNS 979, NND 35)

• 13 years (NNS 781, NND 27)

• 16 years (NNS 570, NND 18)